Sunday, 17 November 2013

Trial for Down's syndrome pregnancy test

A simple blood test during pregnancy which can detect Down's syndrome in the developing foetus is to be trialled by the NHS. The technique, known as Non-Invasive Prenatal Testing (NIPT), could significantly reduce the number of women needing invasive testing, which can cause miscarriage. The study, which is being carried out at Great Ormond Street Hospital, will assess how and when the blood test could be introduced across the NHS.

Currently a woman's risk is assessed using her age, an ultrasound scan, and markers in the blood. Those deemed at high risk of a child with Down's are then offered an invasive test. This involves using a needle to take a sample of either placental cells or of the fluid that bathes the baby - but this procedure carries a 1/100 chance of miscarriage. The aim of the new test is to reduce the number of women having the invasive test by more accurately assessing the risk.

The new blood test, which is already available privately, looks for tiny fragments of DNA from the placenta and the foetus floating in the mother's bloodstream. The test can analyse the free-floating DNA for extra copies of chromosome 21, which is the cause of Down's syndrome. It is thought to be 99% accurate, and those with a positive result will still have the option of undergoing the invasive procedure to confirm the result. Professor Lyn Chitty, from Great Ormond Street who is leading the trial, said; "It could very significantly reduce the number of invasive tests and increase detection, this is seriously exciting stuff and it would be great to get it into the NHS."

The NHS National Institute for Health Research funded trial will analyse the scale of the benefit, as well as the best way to inform mothers and train staff about the test. Professor Chitty explained that one of the very important aspects of the study is looking at ways to make sure women understand the test, so they will therefore know the implications of the results and be able to choose whether or not to have it. Dr Anna Mackie, from the UK National Screening Committee, said: "Early indications suggest that using NIPT to screen women who are found to be at a higher risk of having a baby with Down's syndrome would enable earlier and safer detection of the condition."

It is understood that the new test is approximately 99% accurate for women who have already been identified as being at high risk of having a baby with Down's syndrome. However, the researchers are interested to see whether that accuracy is maintained in women who have not been identified as high risk. The studies for this are still under way, but when they are completed the information obtained could then be provided to women and health professionals to improve understanding.

Jack

Wednesday, 30 October 2013

New understanding of how genes shape face

Scientists are starting to understand why one person's face can look so different from another's. Working on mice, researchers have identified thousands of small regions of DNA that influence the way facial features develop. The study also shows that tweaking genetic material can subtly alter face shape. The findings of the research, which were published in Science, could also help researchers to learn how facial birth defects arise. They said that even though the research was carried out in animals, the human face was likely to develop in the same way.

Professor Axel Visel, from the Joint Genome Institute at the Lawrence Berkeley National Laboratory in California, said: "We're trying to find out how these instructions for building the human face are embedded in human DNA."

The international team has found more than 4,000 "enhancers" in the mouse genome that appear to play a role in facial appearance. These short stretches of DNA act like switches, turning genes on and off. And for 200 of these, the researchers have identified how and where they work in developing mice. Prof Visel said: "In the mouse embryos we can see where exactly, as the face develops, this switch turns on the gene that it controls." The scientists also looked at what happened when three of these genetic switches were removed from mice: "This mice looked pretty normal, but it is really hard for humans to see differences in the face of mice," explained Prof Visel.

By comparing the transgenic mice with unmodified mice, the researchers found that the changes were very subtle. However some mice developed longer or shorter skulls, while others have wider or narrower faces. Prof Visel explained that what this tells us is that this particular gene also plays a role in development if the skull, and can affect what exactly the skull looks like. Understanding this could also help to reveal why and how things can go wrong as embryos develop in the womb, leading to facial birth defects. There are many types of craniofacial birth defects, with cleft lip and cleft palate being the two most common ones. They can affect feeding, speech, breathing, can require extensive surgery and have psychological implications.

Professor Visel added that scientists were just at the beginning of understanding the processes that shape the face, but their early results suggested it was an extremely complex process. He said it was unlikely in the near future that DNA could be used to predict someone's exact appearance, or that parents could alter genetic material to change the way a baby looks.

Jack

Saturday, 19 October 2013

Sleep cleans away brain toxins

Researchers have shown that the brain uses sleep to wash away the waste toxins that build up during a hard day's thinking. The team, from the US, believe that the "waste removal system" is one of the fundamental reasons for sleep. Their study, published in Science, showed that brain cells shrink during sleep to open up the gaps between neurons and allow fluid to wash the brain clean. They also suggest that the failure to clear away some toxic proteins may play a role in some brain disorders.

Another big question for sleep researchers is why do animals sleep at all when it leaves them vulnerable to predators? It has been shown to have a big role in the fixing of memories in the brain and learning, but a team at the University of Rochester Medical Centre believe that "housework" may be one of the primary reasons for sleep. Researcher Dr Maiken Nedergaard said: "The brain only has limited energy at its disposal and it appears that it must choose between two different functional states  - awake and aware or asleep and cleaning up."

Their findings build on last year's discovery of the brain's own network of plumbing pipes - known as the glymphatic system - which carry waste material out of the brain. Scientists, who imaged the brains of mice, showed that the glymphatic system became 10-times more active when the mice were asleep. Cells in the brain, probably the glial cells which keep nerves alive, shrink during sleep. This increases the size of the interstitial space, the gaps between brain tissue, allowing more fluid to be pumped in and wash the toxins away. Dr Nedargaard said this was a "vital" function for staying alive, but did not appear to be possible while the mind was awake. She commented: "This is purely speculation, but it looks like the brain is losing a lot of energy when pumping water across the brain and that is probably incompatible with processing information." She added that the true significance of the findings would be known only after human studies, but doing similar experiments in an MRI machine would be relatively easy.

Commenting on the research Dr Neil Stanley, an independent sleep expert, said: "This is a very interesting study that shows sleep is essential downtime to do some housekeeping to flush out neurotoxins." Many conditions, such as Alzheimer's or Parkinson's disease, which lead to the loss of brain cells are characterised by the build-up of damaged proteins in the brain. The researchers suggest that problems with the brain's cleaning mechanism may contribute to such diseases, but caution more research is needed. The charity Alzheimer's Research UK said more research would be needed to see whether damage to the brain's waste clearance system could lead to diseases like dementia, but the findings offered a "potential new avenue for investigation."

Jack

Tuesday, 15 October 2013

Alzheimer's breakthrough hailed as 'turning point'

The discovery of the first chemical to prevent the death of brain tissue in a neurodegenerative disease has been hailed as the "turning point" in the fight against Alzheimer's disease. A drug that could be taken by patients still needs a lot more work to develop, but scientists say a resulting medicine could treat Alzheimer's, Parkinson's, Huntington's and other diseases.

In tests on mice, the Medical Research Council showed all brain cell death from prion disease could be prevented. Prof Roger Morris, from King's College London, said: "This finding, I suspect, will be judged by history as a turning point in the search for medicines to control and prevent Alzheimer's disease." He went on to say that a cure for Alzheimer's was not imminent but: "I'm very excited, it's the first proof in any living animal that you can delay neurodegeneration. The world won't change tomorrow, but this is a landmark study."

The research team at the Medical Research Council Toxicology Unit, based at the University of Leicester, focused on the natural defence mechanisms built into brain cells. When a virus hijacks a brain cell it leads to a build-up of viral proteins. Cells respond by shutting down almost all protein production in order to halt the spread of the virus. However, many neurodegenerative diseases involve the production of faulty or "misfolded" proteins. These activate the same defences, but with more severe consequences. The misfolded proteins linger and the brain cells shut down protein production for so long that they eventually starve themselves to death. This process is repeated in neurons throughout the brain, and can destroy movement, memory, or even kill, depending on the disease. Safely disrupting this process could treat a wide range of diseases, because it is thought to take place in many forms of neurodegeneration. The researchers halted neurodegeneration by using a compound which prevented those defence mechanisms kicking in.

The study showed mice with prion disease developed severe memory and movement problems, and all of these mice then died within 12 weeks. However, the mice that were given the compound showed no signs of their brain tissue wasting away. Side effects are an issue though, as the compound also acted on the pancreas, meaning the mice developed a mild form of diabetes and lost weight. Any drug given to humans would need to act only on the brain, but this gives scientists and drug companies a starting point which they can then improve on.

Dr Eric Karran, the director of research at the charity Alzheimer's Research UK, said: "Targeting a mechanism relevant to a number of neurodegenerative diseases could yield a single drug with wide-reaching benefits, but this compound is still at an early stage. It will be important for these findings to be repeated and tested in models of other neurodegenerative diseases, including Alzheimer's disease."

Jack

Wednesday, 9 October 2013

Missing genes offer autism clues

A study suggests that the discovery of "missing" genes could help scientists understand how autism develops. US researchers looked at the genetic profiles of more than 431 people with an autism spectrum disorder (ASD) and 379 without. It was found that those with an ASD were more likely to have just one copy of certain genes, when they should have had two. UK experts said genetic factors were one promising area of research into the causes of autism.

About 1% of the population has an ASD. They can run in families - but scientists have not identified a cause. Gene additions or deletions happen in all of us, but it is which genes are affected that determines what the effect is.

Prof Joseph Buxbaum, who led the research team, said: "This is the first finding that small deletions impacting one or two genes appear to be common in autism, and that these deletions contribute to risk of development of this disorder." The researchers found many of the most common deletions in the autistic group were linked to autophagy - a kind of waste-disposal and renewal process for cells. Prof Buxbaum said: "There is good reason to believe that autophagy is really important for brain development because the brain produces many more synapses than it needs, and the excess needs to be pruned back." He explained that having too many or too few synapses both had the effect of not making communication work very well.

Carol Povey, director for the Centre for Autism at the UK's National Autistic Society said: "The causes of autism are still being investigated." Many experts believe that the pattern of behaviour from which autism is diagnosed may not result from a single cause. Therefore more research needs to be done before any concrete conclusions can be drawn about the causes and what this might mean for future developments.

Jack

Tuesday, 1 October 2013

Cancer drugs fund extended until 2016

The prime minister has announced that a £200m-a-year fund for life-enhancing cancer drugs is to continue until 2016. The Cancer Drugs Fund (CDF) was set up in 2011 to help patients in England access certain drugs before they get approval for widespread NHS use. The scheme was due to end next year, but David Cameron has pledged £400m to keep it running.

The move has been welcomed by cancer charities, but Labour accused the prime minister of "letting down" patients.

Sara Osborne, head of policy research at Cancer Research, praised the valuable role the fund would play in battling the disease and highlighted the tens of thousands of people who received treatment because of it. She said: "There's about 30 drugs that are available on the Cancer Drugs Fund, and over the last three years about 34,000 patients have had treatment that they would not have otherwise had, had the fund not existed."

The scheme was only set to continue until 2014 and campaigners raised concerns about where patients would turn for help when the funding ceased. David Cameron said the CDF had been a "massive success" and added that he would recommend its continuation beyond 2016 should he be re-elected. He commented: "People have lived longer and in some cases it has saved people's lives." Mr Cameron also said the government would be partnering with Cancer Research UK to carry out new research into the effectiveness of cancer drugs.

Another charity, Target Ovarian Cancer, said while the news was "positive", it warned it was "just a stop-gap". It highlighted the case of Jenny Bogle who failed to meet CDF criteria for Avastin, a drug shown to delay recurrence. Ms Bogle said: "I have a wealthy friend and an oncologist who are determined to keep me going for as long as possible so I was able to access Avastin privately in the end." She commented that: "It shouldn't be a matter of luck" and pointed out that, if she were living in a different postcode, were vulnerable or less pushy or didn't have the support, she probably would have died years ago.

Alongside the plans to extend the fund, David Cameron also announed that Genomics England - a government-owned organisation tasked with mapping the DNA of 100,000 patients with cancer and rare diseases - will begin a partnership with Cancer Research UK.

Jack

Saturday, 21 September 2013

Brain scan detects tau protein

Japanese scientists have developed a pioneering new brain imaging technique that can detect the build-up of destructive proteins linked to Alzheimer's disease. It could lead to new ways of diagnosing the condition and of testing the effectiveness of new drugs. The technology, reported in the journal Neuron, can identify inside a living brain clumps of a protein called tau that is closely linked to the disease. Alzheimer's Research UK said it was promising work.

Alzheimer's disease is a problem for researchers trying to come up with a cure. The brain starts to die years before any symptoms are detected, which means drugs are probably given too late. A diagnosis of Alzheimer's cannot be made with absolute certainty until a patient has died and their brain is examined. It is also not 100% clear what is the cause of the dementia and what are just symptoms. One protein, called tau, is very closely linked to the disease, with tangles of tau thought to be one way in which brain cells are killed.

The team, lead by the National Institute of Radiological Sciences in Chiba, used positron emission tomography to build a 3D picture of tau in the brain. The researchers developed a chemical that could bind to tau and then be detected during a brain scan.

Dr Magoto Higuchi, from the National Institute of Radiological Sciences in Japan, said: "Positron emission tomography images of tau accumulation... provide robust information on brain regions developing or at risk for tau-induced neuronal death." Dr Eric Karran, director of research at Alzheimer's Research UK, said: "This promising early study highlights a potential new method for detecting tau - a key player in both Alzheimer's and frontotemporal dementia - in the living brain." He also said that, with new drugs being developed to target tau, scans capable of visualising the protein inside the brain could be important for assessing whether treatments in clinical trials are hitting their target. If this method is proven to be effective, such a scan could also be a useful aid for providing people with an accurate diagnosis, as well as for monitoring disease progression.

Jack